Haemonetics Corp. returned to the M&A trail with an agreement to buy Opsens Inc., a cardiology-focused medical device company, for CA$2.90 (US$2.13) per share for a total of CA$345 million (US$253 million). The all-cash transaction, its third significant purchase in five years, is expected to close by late January 2024, pending the approval of regulators and 66.66% of voting shareholders. Haemonetics expects the deal to be immediately accretive to adjusted earnings per share (EPS).
Medical technology company Haemonetics Corp. (HAE) and OpSens, Inc. (OPS.TO, OPSSF.PK) announced Tuesday that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for C$2.
Quebec City heart technology maker OpSens Inc. has agreed to sell itself to Boston healthcare company Haemonetics Corp. for $345-million. It’s the biggest…